2/19/2014 9:04:56 AM
NEW YORK, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced that Mark Pruzanski, M.D., President and Chief Executive Officer, will present at the following investor conferences:
Help employers find you! Check out all the jobs and post your resume.
comments powered by